Linagliptin applicable across wide group of T2DM patients- Latest Indian Position Paper
As per the latest Indian position statement released in the Journal of the Association of Physicians of India, August 2023 issue, Linagliptin therapy is simplifying the management of T2DM with efficacy & applicability across a wide range of patients.
Key expert opinions from this Position paper include:
1. 94.3% of Healthcare Professionals (HCPs) opined that a single 5 mg once daily dosing of linagliptin across diverse T2DM patient profiles, irrespective of cardiac, renal, or hepatic comorbidities, eases up management of T2DM
2. Linagliptin is used in both Drug naïve and uncontrolled T2DM patients.
Linagliptin has multiple clinical and safety advantages across a wide group of T2DM patients, making it potentially an evergreen oral anti-diabetic agent and combination of Linagliptin & Dapagliflozin and Evergreen DUO.
Reference:
Mithal, A., et.al. (2023). Simplifying Type 2 DM Care with Linagliptin: A Position Paper. The Journal of the Association of Physicians of India, 71(8), 11–12. https://doi.org/10.59556/japi.71.0324
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.